Antibody landscapes after influenza virus infection or vaccination

We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advanced virus had the dual benefit of inducing antibodies against both advanced and previous antigenic clusters. These results indicate that preemptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals. Preemptive vaccine updates may substantially improve influenza vaccine efficacy in previously exposed individuals. [Also see Perspective by Lessler] Hills and valleys of influenza infection Each one of us may encounter several different strains of the ever-changing influenza virus during a lifetime. Scientists can now summarize such histories of infection over a lifetime of exposure. Fonville et al. visualize the interplay between protective responses and the evasive influenza virus by a technique called antibody landscape modeling (see the Perspective by Lessler). Landscapes reveal how exposure to new strains of the virus boost immune responses and indicate possibilities for optimizing future vaccination programs. Science, this issue p. 996; see also p. 919

[1]  F. M. Davenport,et al.  A SEROLOGIC RECAPITULATION OF PAST EXPERIENCES WITH INFLUENZA A; ANTIBODY RESPONSE TO MONOVALENT VACCINE , 1956, The Journal of experimental medicine.

[2]  Florian Krammer,et al.  Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis , 2013, Science Translational Medicine.

[3]  René Ecochard,et al.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.

[4]  R. Webster,et al.  DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.

[5]  J. Piercy,et al.  Immunogenicity and protective efficacy of influenza vaccination. , 2004, Virus research.

[6]  R. Webster,et al.  Disquisitions of Original Antigenic Sin. I. Evidence in man. , 1966, The Journal of experimental medicine.

[7]  D. Burke,et al.  Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution , 2013, Science.

[8]  T. Francis,et al.  Epidemiology of influenza; comparative serological observations in England and the United States. , 1955, Lancet.

[9]  P. Horby,et al.  Influenza Infection Rates, Measurement Errors and the Interpretation of Paired Serology , 2012, PLoS pathogens.

[10]  Yan Li,et al.  Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. , 2009, The Journal of infectious diseases.

[11]  F. Horsfall,et al.  NEUTRALIZING ANTIBODIES IN HUMAN SERUM AFTER INFLUENZA A , 1941, The Journal of experimental medicine.

[12]  P. Horby,et al.  Contribution The Epidemiology of Interpandemic and Pandemic Influenza in Vietnam , 2007 – 2010 The Ha Nam Household Cohort Study I , 2012 .

[13]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[14]  M. Sherman,et al.  A Preliminary Report , 1953 .

[15]  L. A. Stone,et al.  Computer Aided Design of Experiments , 1969 .

[16]  R. Compans,et al.  Original Antigenic Sin Responses to Influenza Viruses1 , 2009, The Journal of Immunology.

[17]  G. Lüchters,et al.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.

[18]  D. Sommers,et al.  A longitudinal analysis , 1992 .

[19]  W G Laver,et al.  Molecular mechanisms of variation in influenza viruses , 1982, Nature.

[20]  R. Greenlee,et al.  Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. , 2009, The Journal of infectious diseases.

[21]  Recommended composition of influenza virus vaccines for use in the 2010 influenza season (southern hemisphere winter). , 2009, Releve epidemiologique hebdomadaire.

[22]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[23]  Keyao Pan Understanding Original Antigenic Sin in Influenza with a Dynamical System , 2011, PloS one.

[24]  K. Subbarao,et al.  Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus , 2014, Clinical and Vaccine Immunology.

[25]  A. Monto Epidemiology of influenza. , 2008, Vaccine.

[26]  T. Francis,et al.  Studies of antibodies to strains of influenza virus in persons of different ages in sera collected in a postepidemic period. , 1955, Journal of immunology.

[27]  Gavin J. D. Smith,et al.  Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China , 2012, PLoS pathogens.

[28]  M. Diamond,et al.  Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants , 2011, The Journal of experimental medicine.

[29]  W. Fitch,et al.  Positive Darwinian evolution in human influenza A viruses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Thomas Francis,et al.  EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.

[31]  M. Ventresca,et al.  Prevalence of Antibodies against Seasonal Influenza A and B Viruses in Children in Netherlands , 2011, Clinical and Vaccine Immunology.

[32]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[33]  Keiji Fukuda,et al.  Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. , 2010, Vaccine.

[34]  A S Perelson,et al.  Variable efficacy of repeated annual influenza vaccination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. K. Hirst THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION , 1942, The Journal of experimental medicine.

[36]  T. Francis,et al.  Experience with Vaccination Against Influenza in the Spring of 1947: A Preliminary Report. , 1947, American journal of public health and the nation's health.